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As global health services respond to the coronavirus pandemic, many prescribers 31 
are turning to experimental drugs. This review aims to assess the risk of drug-drug 32 
interactions in the severely ill COVID-19 patient.  33 
Experimental therapies were identified by searching Clinicaltrials.gov for COVID-19, 34 
2019-nCoV, 2019 novel coronavirus, SARS-CoV-2. The last search was performed 35 
on 30th June 2020. Herbal medicines, blood-derived products, and in vitro studies 36 
were excluded. We identified comorbidities by searching PubMed for the MeSH 37 
terms “COVID-19”, “Comorbidity” and “Epidemiological Factors”. Potential drug-drug 38 
interactions were evaluated according to known pharmacokinetics, overlapping 39 
toxicities, and QT risk. Drug-drug interactions were graded GREEN and YELLOW: 40 
no clinically significant interaction; AMBER: caution; RED: serious risk. 41 
A total of 2,378 records were retrieved from ClinicalTrials.gov, which yielded 249 42 
drugs that met inclusion criteria. Thirteen primary compounds were screened against 43 
512 comedications. A full database of these interactions is available at www.covid19-44 
druginteractions.org.  45 
Experimental therapies for COVID-19 present a risk of drug-drug interactions, with 46 
lopinavir/ritonavir (10% RED, 41% AMBER; mainly perpetrator of pharmacokinetic 47 
interactions but also risk of QT prolongation particularly when given with concomitant 48 
drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 49 
27% AMBER, victim of some interactions due to metabolic profile but also 50 
perpetrator of QT prolongation) posing the greatest risk. With management, these 51 
risks can be mitigated. We have published a drug-drug interaction resource to 52 
facilitate medication review for the critically ill patient. 53 
 
 54 
Synopsis 232 words 55 
 56 




“Desperate times call for desperate remedies”. But what if experimental treatments 61 
for COVID-19 have a risk of causing harm in the very group of individuals most in 62 
need of such therapies? And what if the majority of these harms remain 63 
unrecognised? Drug-drug interactions involving two or more drugs have long been 64 
recognised as having the potential to cause harm. In vitro data, clinical studies in 65 
healthy volunteers, and patients (usually evaluating the magnitude of change in drug 66 
exposure in the blood stream), and expert interpretation are the main tools to point to 67 
the likelihood of a clinically significant drug-drug interaction. However, it is important 68 
to recognise that for patients with multiple morbidities who may have organ 69 
dysfunction there is a real risk of increased susceptibility to adverse effects and 70 
therefore the same drug-drug interaction may be more likely to result in harm. 71 
People requiring experimental COVID-19 therapies will often be clinically unstable, 72 
and the development of toxicities from drug-drug interactions may easily be 73 
misattributed. 74 
 75 
Since 1998, the University of Liverpool has established a prescribing resource for 76 
managing drug-drug interactions in individuals receiving antiretroviral therapy to treat 77 
or prevent HIV.1 The database contains a review of over 31,000 drug interactions, 78 
 
synthesised from data systematically collected from medical and scientific literature, 79 
information from drug regulatory authorities or expert opinion. Mirroring the principles 80 
of GRADE,2 drug interaction assessments are based on predetermined criteria, with 81 
critical evaluation of the quality of evidence. The Liverpool methodology is published3 82 
and has been used in the review process for national and international treatment 83 
guidelines [e.g. WHO4, BHIVA5]. A similar drug-drug interaction resource was 84 
developed for hepatology6 in 2011, and, together with Radboudumc, Nijmegen, the 85 
Netherlands, for cancer7 in 2018. In March 2020, we published a drug-drug 86 
interaction (DDI) resource for experimental COVID therapies [www.covid19-87 
druginteractions.org]. This review summarises the methodology and processes 88 
undertaken to establish the resource. 89 
 90 
Why is this review needed? 91 
 92 
 93 
Use of experimental COVID-19 therapies is rapidly evolving, and steadily increasing. 94 
Whilst initial use was in the sickest individuals (who are also most likely to have 95 
multiple comorbidities and polypharmacy), wider deployment as prophylaxis (e.g. to 96 
frontline health workers) is being considered.8-10 Several of these experimental 97 
therapies have the propensity for drug-drug interactions which may cause clinical 98 
harms. A review of potential for interactions with drugs used for common 99 
comorbidities, or frequently used in the intensive care setting is urgently needed. 100 
Resulting knowledge will be collated, curated, and made readily available to support 101 





Identifying Experimental Therapies 106 
 107 
Experimental therapies for COVID-19 were identified by searching Clinicialtrials.gov 108 
using the following search terms: COVID-19, 2019-nCoV, 2019 novel coronavirus, 109 
and SARS-CoV-2. The last search was run on 30th June 2020. Experimental 110 
therapies were selected for inclusion as a primary drug for drug-drug interaction 111 
analysis on the following basis i) use for treatment or prevention of COVID-19, ii) use 112 
in randomised controlled trials which are multi-country, or multi-centre within one 113 
country, iii) widespread use outside of randomised trials if listed as options to 114 
consider from national bodies and specialist societies. Our evaluation panel 115 
comprising senior/principal pharmacists, academic pharmacologists, and an 116 
Infectious Diseases specialist (CM, FM, AB, DBa, DBu, SK) discussed potential 117 
inclusion for all candidates identified. We excluded compounds where only in vitro 118 
data were available, as well as blood-derived products such as serum from 119 
recovered patients, and herbal and traditional medicines.  120 
  121 
Identifying comedications 122 
 123 
We utilised a semi-systematic approach to selection of drug classes to include as 124 
comedications. Briefly, we first gathered evidence on the frequency and type of 125 
comorbidities reported in individuals with severe COVID-19 disease (using MeSH 126 
terms “COVID-19” [supplementary concept], “Comorbidity” and “Epidemiological 127 
Factors”). We then identified commonly used classes of compounds for these 128 
 
comorbidities from UK treatment guidelines (e.g. NICE).11 Within each therapeutic 129 
class, we then selected a list of drugs which were most frequently used across 130 
Europe and North America (we have previously made this selection based on 131 
country guidelines and the input of our International Editorial Board for HIV). 132 
 133 
In addition to high-frequency comorbidities in severe COVID-19 patients, we also 134 
selected comedications likely to be used in disease management as well as those 135 
associated with high-consequence drug-drug interactions. These included drugs 136 
used in anaesthetics and intensive care, drugs used for treating symptoms or 137 
complications of COVID-19, and commonly used narrow therapeutic index drugs. 138 
 139 
Evaluation of potential DDIs 140 
 141 
Drug-drug interactions were identified as previously described by Seden et al.3 142 
Briefly, data on the clinical pharmacology of experimental therapies were extracted 143 
from approved product labels, published submissions to regulatory authorities in 144 
Europe, USA and Japan,12-23 published case reports or studies and, where none of 145 
the above were available, from personal communication with the manufacturer. 146 
Propensity for a drug interaction was based on screening against known pathways 147 
for absorption, distribution, metabolism, and excretion of all drugs involved. This 148 
included potential for induction and inhibition of enzymes and transporters, 149 
interactions affecting bioavailability, protein binding and hepatic/renal excretion. 150 
Additional considerations included overlapping toxicities and potential interactions 151 
involving drugs with a narrow therapeutic index (e.g. anti-arrhythmics, anti-152 
coagulants). A significantly increased risk in QT prolongation as a result of 153 
 
combining two drugs with known risk of torsade de pointes,24 or else a drug 154 
interaction leading to elevated concentrations of a drug with known risk of torsade or 155 
QT prolongation were separately coded.  156 
Details of how drug interaction evaluations are made with regard to strength of 157 
recommendation and quality of evidence underpinning that recommendation have 158 
been previously published,24 and were undertaken by our evaluation panel (see 159 
above).  160 
 161 
For our COVID-19 recommendations we also took the following additional 162 
considerations into account when assessing drug interactions: i) the likely critical 163 
condition of any patient requiring these therapies, ii) the relatively short duration of 164 
coadministration, iii) the incremental risks to health workers from additional 165 
monitoring, iv) available, safer alternatives, and v) the option of pausing the 166 
comedication whilst COVID-19 therapy is administered.  167 
 168 
Interactions were graded into four levels: GREEN: no clinical significant interaction 169 
expected; YELLOW: potential interaction likely of weak intensity, additional 170 
action/monitoring or dosage adjustment unlikely to be required; AMBER: potential 171 
interaction that may require close monitoring, alteration of drug dosage or timing of 172 
administration; RED: these drugs should not be coadministered. The decision to give 173 
or withhold drugs is always the responsibility of the prescriber. A pragmatic use of 174 
our drug-drug interaction recommendations is to regard GREEN and YELLOW flags 175 
as an indication that no clinically significant drug-drug interactions exist, while RED 176 
flags indicate significant cause for concern. An AMBER flag does not preclude 177 
coadministration (since drug-drug interactions can usually be managed or monitored) 178 
 
but rather indicates the need to consider risks and benefits in that individual patient 179 
for whom treatment is considered. 180 
The DDI grading of the antiretroviral drug lopinavir/ritonavir is mostly similar between 181 
the COVID-19 and the HIV websites with the exception of contraceptives or 182 
antidepressants devoid of QT risk. The DDI has been downgraded on the COVID-19 183 
site given the short treatment course making monitoring or dose adjustment of these 184 
therapeutic agents unnecessary. Another DDI grading difference relates to strong 185 
enzyme inducers (e.g. carbamazepine, phenytoin, St John’s Wort) which are 186 
contraindicated in the COVID-19 website with drugs metabolized by cytochrome 187 




Experimental COVID-19 Therapies 192 
 193 
As a new and evolving pandemic, it is unsurprising that little consensus has been 194 
reached between national and international guidelines and specialist societies 195 
surrounding the use and choice of experimental therapies, and the number of 196 
potential therapeutic compounds is rapidly increasing.25-33 Therefore, our range of 197 
experimental therapies will necessarily be expanded over the coming weeks and 198 
months. 199 
 200 
As of 30th June 2020, a total of 2,378 clinical trials were retrieved from 201 
ClinicalTrials.gov. Two hundred and forty-nine drugs from ClinicalTrials.gov met our 202 
inclusion criteria. The drugs listed included 27 antivirals, 48 immunotherapy drugs, 203 
 
five anti-malarial drugs, six glucocorticoids, and 163 miscellaneous compounds with 204 
different modes of action. 205 
 206 
After selection for inclusion as a primary drug for drug-drug interaction analysis 207 
based on the criteria above, the following thirteen drugs were taken forward for 208 
analysis of drug-drug interactions: anakinra, baricitinib, chloroquine, favipiravir 209 
hydroxychloroquine, interferon , lopinavir/ritonavir, nitazoxanide, remdesivir, 210 
ribavirin, ruxolitinib, sarilumab and tocilizumab. We did not include azithromycin in 211 
this review, as the reasons for giving this drug appeared to be in part for use in 212 
preventing bacterial superinfection rather than as a true adjuvant. Dexamethasone 213 
which has recently been shown in the RECOVERY trial to reduce 28-day mortality in 214 
patients hospitalised with COVID-19 receiving invasive mechanical ventilation or 215 
oxygen, will be added to the COVID drug interaction site soon.34 216 
 217 
DDI Potential of COVID-19 Therapies 218 
 219 
Table 1 summarises the key interaction information for each experimental therapy. A 220 
comprehensive breakdown of interaction potential and references are given in 221 
Supplemental Table 1.  222 
One main source of risk is inhibition of CYP3A4 by lopinavir/ritonavir (perpetrator). 223 
Given that ritonavir inhibits irreversibly CYP3A4, the inhibitory effect may last up to 224 
five days after stopping/ritonavir.35 On the other hand, lopinavir/ritonavir induces 225 
CYP1A2, CYP2C9, CYP2C19 and glucuronidation. Increase in CYP activity has 226 
been observed even after short course treatment with lopinavir/ritonavir.36  The 227 
resolution of the inducing effect can take up to three weeks. Thus, monitoring of 228 
 
narrow therapeutic index drugs is warranted during and after stopping treatment with 229 
lopinavir/ritonavir. COVID-19 drugs are also potential victims of a drug-drug 230 
interaction when coadministered with strong cytochrome P450 (CYP) inducers, as 231 
are chloroquine, hydroxychloroquine, and remdesivir. Drug-drug interactions with 232 
involvement of P-glycoprotein (P-gp) may also have clinical relevance as both 233 
chloroquine and hydroxychloroquine are moderate P-gp inhibitors. 234 
 235 
In addition to drug-drug interactions that have a pharmacokinetic basis (i.e. a change 236 
in drug exposure), pharmacodynamic drug-drug interactions can also be relevant, in 237 
particular because chloroquine, hydroxychloroquine and lopinavir/ritonavir can cause 238 
QTc prolongation, and combined use with other drugs which prolong the QTc should 239 
be avoided. 240 
 241 
The most frequent comorbidities in patients with severe COVID-19 are hypertension, 242 
cardiovascular, and cerebrovascular disease, diabetes, malignancy, gastrointestinal 243 
disease, and respiratory system disease.37-40 By including the different classes of 244 
treatments for each of these morbidities, and selecting other medicines used to 245 
support critical care or manage symptoms of COVID-19 disease, we identified a total 246 
of 512 comedications to screen against experimental COVID-19 therapies.  247 
 248 
A full database of our drug-drug interaction recommendations is posted on 249 
www.covid19-druginteractions.org. This website is continuously updated as more 250 
comedications and further therapies for COVID-19 are added. Interactions between 251 
experimental COVID-19 drugs and comedications, may be searched, but not 252 
interactions between comedications. The interaction checker focuses on PK 253 
 
interactions, but also warns for overlapping toxicity. Possible physicochemical 254 
interactions occurring in an infusion or syringe have not been addressed. We have 255 
also published prescribing resources advising how to administer experimental 256 
therapies in the case of swallowing difficulties, and renal or hepatic insufficiency. 257 
Examples of recommendations with the anti-coagulant, anti-platelet, and fibrinolytic 258 
class; antidiabetic class; and antibiotic class can be seen in figure 1. 259 
 260 
As of 30th June 2020, a total of 512 comedications were screened against the 13 261 
primary compounds. The number (frequency) of RED and AMBER flags for 262 
experimental agents were as follows: anakinra 8 (2%) and 9 (2%), respectively, 263 
baricitinib 7 (1%) and 12 (2%), chloroquine 35 (7%) and 138 (27%), favipiravir 0 (0%) 264 
and 14 (3%), hydroxychloroquine 35 (7%) and 138 (27%), interferon beta 1 (0%) 13 265 
(3%), lopinavir/ritonavir 52 (10%) and 209 (41%) nitazoxanide 0 (0%) and 4 (1%), 266 
remdesivir 9 (2%) and 0 (0%), ribavirin 2 (0%) and 16 (3%), ruxolitinib 7 (1%) and 66 267 
(13%), sarilumab 7 (1%) and 9 (2%), and tocilizumab 7 (1%) and 9 (2%).   268 




Experimental COVID-19 therapies carry significant risk for drug-drug interactions. 272 
Amongst these treatments, drug interactions involving the HIV protease inhibitor 273 
lopinavir/ritonavir was most frequent, followed by chloroquine, hydroxychloroquine, 274 
and ruxolitinib, with anakinra, baricitinib, favipiravir, interferon   nitazoxanide, 275 
ribavirin, remdesivir, sarilumab, and tocilizumab having low propensity for drug 276 
interactions.  277 
Assessing the likelihood of a drug interaction is not always straightforward. Whilst 278 
the magnitude of change in exposure of either or both drugs can be quantified 279 
through a clinical study, the clinical relevance may vary according to the therapeutic 280 
index of the affected compound. Pharmacodynamic interactions (including 281 
overlapping toxicities) can be equally complex to judge, as in the case of drugs 282 
which cause QT prolongation, and which may also have exposures increased by a 283 
drug interaction. Regulatory authorities in the US and EU may consequently differ in 284 
evaluation of risk and recommendations, e.g. with HIV boosted protease inhibitors 285 
and quetiapine.1 286 
 287 
A potential weakness in our evaluation process is that the majority of the drug-drug 288 
interactions have never been studied, resulting in judgements based on ‘expert 289 
opinion’. We have therefore assigned the lowest quality of evidence to these 290 
evaluations. These evaluations will be continually reviewed as data emerge and will 291 
be updated on www.covid19-druginteractions.org. The rapidly evolving nature of the 292 
COVID-19 field makes keeping the list of drugs up-to-date more challenging than our 293 
HIV, hepatitis, and cancer websites. We run the ClinicalTrials.gov search regularly to 294 
 
identify new experimental COVID-19 therapies and survey our users as to which 295 
drugs they would find useful. We constantly review evidence, refine our interactions, 296 
and remove medications that are no longer in use. We propose to further develop 297 
the accessibility of the database by developing an app which will allow interactions to 298 
be view offline. 299 
 300 
Risk of drug interactions should not necessarily preclude use of experimental 301 
therapies for COVID-19 since they are often manageable. For example, in critically ill 302 
patients, consideration should be given to stopping all but essential medications.  303 
Often there will be a need to balance the risk of "theoretical" drug interactions 304 
against the benefit (often incompletely quantified) of new therapies. Safe 305 
management of drug interactions can only be carried out when prescribers are 306 
aware of their presence, underlining the importance of a full medicines reconciliation 307 
even for patients who present unwell and who are unable to give a detailed history. 308 
Our online resource is an attempt to increase recognition of harmful drug interactions 309 
and promote safe prescribing in critically unwell patients during the COVID-19 310 
pandemic.  311 
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Table 1. Drug Interaction Risk of Experimental COVID-19 Therapies. BCRP 518 
breast cancer resistance protein, CYP cytochrome P450, MATE multidrug and toxic 519 
compound extrusion, OAT organic anion transporter, OATP organic anion 520 
transporting polypeptide, P-gp P-glycoprotein, QTc corrected QT interval, TdP 521 
torsades des pointes. 522 
 523 
Experimental Therapy Interaction Potential  
Anakinra No effect on CYP450 per se but anakinra reverses interleukin induced 
suppression of cytochromes (e.g. IL-1 elevation during inflammation). 
Currently no a priori adjustment of CYP substrates needed.  
No effect on QTc.41 
Baricitinib Partially metabolized by CYP3A4 and a substrate for OAT3, P-gp, 
BCRP, and MATE2-K. May inhibit OCT1. Strong inhibitors of inducers 
of CYP3A4 are unlikely to significantly alter baricitinib exposure. 
Transporters inhibitors, with the exception of OAT3 inhibitors, are 
unlikely to cause a significant effect on baricitinib exposure. 
No effect on QTc.42 
Chloroquine A moderate inhibitor of CYP2D6 and P-gp and caution may be 
required when coadministering comedications metabolized or 
transported by these pathways with a narrow therapeutic index. 
Shown to prolong QTc and is on the known risk of TdP list.24 
Favipiravir Metabolized mainly by aldehyde oxidase (AO). Based on metabolism 
and clearance, clinically significant drug interactions are minimal. It 
does inhibit CYP2C8 and caution is required in combination with 
comedications metabolized by this route and AO. 
The QT prolongation risk is considered to be low.22, 43 
Hydroxychloroquine A moderate inhibitor of CYP2D6 and P-gp and caution may be 
required when coadministering comedications metabolized or 
transported by these pathways with a narrow therapeutic index. 
Shown to prolong QTc and is on the known risk of TdP list.24 
Interferon  Drug interaction potential not fully evaluated. May reduce the activity 
of CYP enzymes but the clinical significance is likely to be small.  
No effect on QTc.44 
Lopinavir/ritonavir Inhibits CYP3A as well as some key transporters: P-gp, BCRP and 
OATP1B1. Many drug interactions of clinical importance due to 
increased exposure of comedications using these pathways. Also, 
potential to decrease exposure of some drugs metabolized by other 
CYP enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19) and 
glucuronidation. 
Known to cause QT prolongation and is on the Possible Risk of TdP 
list.24 
Nitazoxanide Rapidly hydrolyzed to tizoxanide; in vitro studies indicate nitazoxanide 
is unlikely to inhibit cytochromes. Tizoxanide is highly protein-bound 
(>99%), so caution is indicated when give with other highly protein-
bound drug with narrow therapeutic indices. 
No effect on QTc.45, 46 
 
Remdesivir A prodrug predominantly metabolized by hydrolase activity. Based on 
rapid distribution, metabolism and clearance after i.v. administration, 
the likelihood of clinically significant interactions is low.  
No effect on QTc.23 
Ribavirin There is minimal potential for CYP450 or transporter-based 
interactions. 
No effect on QTc.15 
Ruxolitinib Metabolized by CYP3A4 and CYP2C9, ruxolitinib has the potential to 
be a victim of drug-drug interactions perpetrated by inhibitors or 
inducers of these enzymes. Ruxolitinib may inhibit BCRP and P-gp 
and caution is indicating with coadministering with substrates of these 
transporters with narrow therapeutic indices.47 
Sarilumab No effect on CYP450 per se but sarilumab reverses interleukin 
induced suppression of cytochromes (e.g. IL-6 elevation during 
inflammation). Currently no a priori adjustment of CYP substrates 
needed.  
No effect on QTc.48 
Tocilizumab No effect on CYP450 per se but tocilizumab reverses interleukin 
induced suppression of cytochromes (e.g. IL-6 elevation during 
inflammation). Currently no a priori adjustment of CYP substrates 
needed.  
No effect on QTc.18 
 524 
 525 
Figure 1. Predicted drug-drug interactions between anti-coagulant, anti-526 
platelet, and fibrinolytic drug therapies and antiviral experimental COVID-19 527 
drugs or anti-inflammatory experimental COVID-19 drugs. GREEN = no clinically 528 
relevant interaction, YELLOW = potential weak interaction, AMBER = potential 529 
interaction which may require dose modification or monitoring, RED = do not 530 
coadminister. Arrows indicate the potential for increased, decreased or unchanged 531 
exposure of the comedication (solid arrows) or experimental therapy (open arrows). 532 
 = these drugs have been identified by www.CredibleMeds.org as having a risk of 533 
QT prolongation and/or torsades des pointes. The risk may be concentration- or 534 
dose-related and/or additive if two or more such drugs are combined. Note, please 535 
check product labels for any additional cardiac warnings. Quality of evidence for PK 536 
interactions were assessed according to the principles of GRADE. Grades are High 537 
(1), Moderate (2), Low (3) and Very Low (4) as previously described by Seden et al.3 538 
 
CLQ chloroquine, FAVI favipiravir, HCLQ hydroxychloroquine, INF  interferon, 539 
LPV/r lopinavir/ritonavir, NTZ nitazoxanide, RDV remdesivir, RBV ribavirin, TCZ 540 
tocilizumab. 541 
 542 
Anti-viral experimental COVID-19 drugs 543 
 544 
 CLQ  FAVI HCLQ  IFN-β LPV/r  NTZ RDV RBV 
Acenocoumarol   4  4  4  4  449, 50  4  4  4 
Apixaban  4  4  4  4  351  4  4  4 
Argatroban  4  4  4  4  4  4  4  4 
Aspirin  4  4  4  4  4  4  4  4 
Betrixaban   4  4   4  4   4  4  4  4 
Clopidogrel   4  4  4  4  352-55  4  4  4 
Dabigatran  4  4  4  4  or  256  4  4  4 
Dalteparin  4  4  4  4  4  4  4  4 
Dipyridamole  4  4  4  4  4  4  4  4 
Edoxaban  4  4  4  4  4  4  4  4 
Eltrombopag  4  4  4  4  17% 357  4  4  4 
Enoxaparin  4  4  4  4  4  4  4  4 
Fondaparinux  4  4  4  4  4  4  4  4 
Heparin  4  4  4  4  4  4  4  4 
Phenprocoumon   4  4  4  4  4  4  4  4 
Prasugrel  4  4  4  4  454, 58  4  4  4 
Rivaroxaban  4  4  4  4  459  4  4  4 
Streptokinase  4  4  4  4  4  4  4  4 
Ticagrelor  4  4  4  4 4  4  4  4 
Tinzaparin  4  4  4  4  4  4  4  4 
Warfarin   4  4  4  4  436, 60, 61  4  4  462, 63 
 545 
Anti-inflammatory experimental COVID-19 drugs. 546 
 547 
 Anakinra Baricitinib Ruxolitinib Sarilumab Tocilizumab 
Acenocoumarol   4  4  4  4  4 
Apixaban  4  4  4  4  4 
Argatroban  4  4  4  4  4 
Aspirin  4  4  4  4  4 
Betrixaban  4  4  4  4  4 
Clopidogrel   4  4  4  4  4 
Dabigatran  4  4  4  4  4 
Dalteparin  4  4  4  4  4 
Dipyridamole  4  4  4  4  4 
Edoxaban  4  4  4  4  4 
Eltrombopag  4  4  4  4  4 
Enoxaparin  4  4  4  4  4 
Fondaparinux  4  4  4  4  4 
Heparin  4  4  4  4  4 
Phenprocoumon   4  4  4  4  4 
Prasugrel  4  4  4  4  4 
 
Rivaroxaban  4  4  4  4  4 
Streptokinase  4  4  4  4  4 
Ticagrelor  4  4  4  4  4 
Tinzaparin  4  4  4  4  4 
Warfarin   4  4  4  4  4 
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